These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 8878582

  • 1. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
    Brun-Pascaud M, Chau F, Garry L, Jacobus D, Derouin F, Girard PM.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2067-70. PubMed ID: 8878582
    [Abstract] [Full Text] [Related]

  • 2. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.
    Brun-Pascaud M, Chau F, Simonpoli AM, Girard PM, Derouin F, Pocidalo JJ.
    J Infect Dis; 1994 Sep; 170(3):653-8. PubMed ID: 8077724
    [Abstract] [Full Text] [Related]

  • 3. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
    Mehlhorn H, Dankert W, Hartman PG, Then RL.
    Parasitol Res; 1995 Sep; 81(4):296-301. PubMed ID: 7624286
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
    Martinez A, Allegra CJ, Kovacs JA.
    Am J Trop Med Hyg; 1996 Mar; 54(3):249-52. PubMed ID: 8600759
    [Abstract] [Full Text] [Related]

  • 5. Experimental evaluation of roxithromycin combined with dapsone or sulphamethoxazole on Pneumocystis carinii and Toxoplasma gondii dual infections in a rat model.
    Brun-Pascaud M, Chau F, Derouin F, Girard PM.
    J Antimicrob Chemother; 1998 Mar; 41 Suppl B():57-62. PubMed ID: 9579714
    [Abstract] [Full Text] [Related]

  • 6. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
    Chang HR, Arsenijevic D, Comte R, Polak A, Then RL, Pechère JC.
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1803-7. PubMed ID: 7986011
    [Abstract] [Full Text] [Related]

  • 7. Lack of activity of artemether for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii infections in rat.
    Brun-Pascaud M, Chau F, Derouin F, Girard PM.
    Parasite; 1996 Jun; 3(2):187-9. PubMed ID: 8758556
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.
    Walzer PD, Kim CK, Foy JM, Linke MJ, Cushion MT.
    Antimicrob Agents Chemother; 1988 Jan; 32(1):96-103. PubMed ID: 3258144
    [Abstract] [Full Text] [Related]

  • 9. Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.
    Brun-Pascaud M, Rajagopalan-Levasseur P, Chau F, Bertrand G, Garry L, Derouin F, Girard PM.
    Antimicrob Agents Chemother; 1998 May; 42(5):1068-72. PubMed ID: 9593128
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
    Rosowsky A, Papoulis AT, Forsch RA, Queener SF.
    J Med Chem; 1999 Mar 25; 42(6):1007-17. PubMed ID: 10090784
    [Abstract] [Full Text] [Related]

  • 11. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
    Piper JR, Johnson CA, Krauth CA, Carter RL, Hosmer CA, Queener SF, Borotz SE, Pfefferkorn ER.
    J Med Chem; 1996 Mar 15; 39(6):1271-80. PubMed ID: 8632434
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist.
    Hughes WT, Jacobus DP, Canfield C, Killmar J.
    Antimicrob Agents Chemother; 1993 Jul 15; 37(7):1417-9. PubMed ID: 8363369
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans.
    Dhople AM.
    J Antimicrob Chemother; 2001 Jan 15; 47(1):93-6. PubMed ID: 11152437
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
    Walzer PD, Foy J, Steele P, White M.
    Antimicrob Agents Chemother; 1993 Jul 15; 37(7):1436-43. PubMed ID: 8363372
    [Abstract] [Full Text] [Related]

  • 20. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J, Zamora L, Gatell JM, Miró JM, Vernet E, Valls ME, Soriano E, SanMiguel JG.
    AIDS; 1993 Jan 15; 7(1):59-64. PubMed ID: 8442918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.